CHE at a glance
Chemed Corp (CHE, SEC CIK 19584) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Chemed Corp (CHE) reported revenue of $2.5 billion (up 4.1% from FY2024) and net income of $265.2 million. Diluted EPS was $18.34.
- As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Chemed Corp (CHE) shares worth $3.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by LEE SPENCER S on November 11, 2026 of 1,000 shares at $547.61 per share.
- In the last 90 days, CHE insiders reported 0 open-market purchases ($0) and 5 open-market sales ($4.1M) on Form 4, a net sale of $4.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.5B
- +4.1% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$4.1M
- 13F holders
- 39 funds
- $3.1B · +1 vs prior quarter
- Latest 8-K
- Oct 27, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the latest 10-K and prior 10-Q
- Carried-forward regulatory, operational, market, and financial risks remain applicable
Management Discussion & Analysis
- Q3 revenue $690.9M, up 10.6% YoY from $624.9M, led by VITAS up 12.2%
- Gross margin 33.7% vs 32.0% YoY, adjusted EBITDA margin 19.4% vs 17.4%
- Best segment VITAS: revenue $457.4M, net income $65.7M, after-tax margin 14.4% vs 11.5%
- Worst segment Roto-Rooter: net income $30.1M vs $32.1M, after-tax margin 13.0% vs 14.8%
- Operating cash flow decreased $25.1M; debt rose $236.0M and treasury stock increased $400.0M from repurchases and acquisitions
- Outlook: no material FY2026 impact expected, but inflation, tariffs, fuel costs and Iran-related fuel pressures threaten future profitability
AI summary of the CHE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026, covering Chemed’s latest operating performance
- Press release furnished as Exhibit 99, containing the detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $690.9M, up 10.6%; GAAP EPS $5.45, up 22.2%, adjusted EPS $6.75, up 28.1%
- VITAS drove earnings: revenue $457.4M, ADC up 9.4%, adjusted EBITDA up 31.4% to $92.5M
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for quarter ended June 30, 2026
- Investor-relevant financial details contained in furnished Exhibit 99 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $673.3M, up 8.8%; GAAP EPS $5.13, up 43.7%, adjusted EPS $6.06, up 41.9%
- VITAS drove upside: revenue $443.3M, up 11.9%; adjusted EBITDA $80.6M, up 20.6%, margin 18.2%
AI summaries of CHE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CHE
Don't miss the next CHE filing
- Alerts as it files. A push when CHE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CHE, by share count.
- Ask anything. An AI agent that reads every CHE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LEE SPENCER S | G | Nov 13, 2026 | 60 | - |
| LEE SPENCER S | Sell | Nov 11, 2026 | 1,000 | $547.61 |
| MCNAMARA KEVIN J | Sell | Nov 3, 2026 | 2,000 | $537.90 |
| LEE SPENCER S | Sell | Nov 2, 2026 | 920 | $537.17 |
| Wherley Joel L | A | Oct 20, 2026 | 12,686 | $512.64 |
| HUTTON THOMAS C | A | Oct 20, 2026 | 3,964 | $512.64 |
| Witzeman Michael D | A | Oct 20, 2026 | 12,686 | $512.64 |
| MCNAMARA KEVIN J | A | Oct 20, 2026 | 36,693 | $512.64 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4B | $2.5B |
| Operating Income | - | $366.5M | $338.2M |
| Net Income | $272.5M | $302.0M | $265.2M |
| Op. Margin | - | 15.1% | 13.4% |
| Net Margin | - | 12.4% | 10.5% |
| Balance Sheet | |||
| Total Assets | $1.7B | $1.7B | $1.5B |
| Equity | - | $1.1B | $979.4M |
| ROE | - | 27.0% | 27.1% |
| Per Share | |||
| EPS | $17.93 | $19.89 | $18.34 |
| Cash Flow | |||
| Operating CF | - | $417.5M | $388.3M |
| CapEx | $56.9M | $49.5M | $62.8M |
Source: XBRL data in Chemed Corp (CHE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CHE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 39 | $3.09B |
| Q2 2026 | 38 | $2.90B |
| Q1 2026 | 38 | $2.30B |
| Q4 2025 | 35 | $2.58B |
| Q3 2025 | 36 | $2.91B |
| Q2 2025 | 35 | $2.92B |
| Q1 2025 | 36 | $2.86B |
| Q4 2024 | 31 | $2.18B |
- Vanguard Portfolio Management LLC+68.5K (+9%)
- Morgan Stanley+23.5K (+10%)
- Franklin Resources+14.5K (+163%)
- D.E. Shaw & Co+13.8K (+225%)
- Dimensional Fund Advisors+10.7K (+4%)
- AQR Capital Management−112.8K (-12%)
- Goldman Sachs Group−43.7K (-24%)
- BlackRock−31.7K (-2%)
- Bank of America Corp−26.0K (-25%)
- Vanguard Capital Management LLC−17.8K (-3%)
- Citadel Advisors LLC+16.5K
- Allstate+748
- FMR LLC (Fidelity)−29.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CHE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- AHCO · AdaptHealth Corp.Services-Home Health Care Services
- ADUS · Addus HomeCare CorpServices-Home Health Care Services
- AVAH · Aveanna Healthcare Holdings, Inc.Services-Home Health Care Services
- BTSG · BrightSpring Health Services, Inc.Services-Home Health Care Services
- EHAB · Enhabit, Inc.Services-Home Health Care Services
- OPCH · Option Care Health, Inc.Services-Home Health Care Services
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CHE SEC filings: frequently asked questions
Are CHE insiders buying or selling?
In the last 90 days, Chemed Corp (CHE) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $4.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CHE stock?
As of September 30, 2026, the largest Chemed Corp (CHE) holders among the 13F filers tracked by SignalX were BlackRock ($733.6 million), AQR Capital Management ($434.2 million), Vanguard Portfolio Management LLC ($432.1 million), Vanguard Capital Management LLC ($296.3 million), State Street Corp ($221.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CHE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Chemed Corp (CHE) reported revenue of $2.5 billion (up 4.1% from FY2024) and net income of $265.2 million. Diluted EPS was $18.34. The figures come from the XBRL data in the 10-K.
What did CHE report in its latest 8-K?
Chemed Corp (CHE) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026, covering Chemed’s latest operating performance.
What are the latest CHE SEC filings?
Chemed Corp (CHE) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on November 16, 2026.
What is CHE's SEC CIK number?
Chemed Corp (CHE)'s SEC Central Index Key (CIK) is 19584. EDGAR lists every CHE filing under that number.
Ask anything about CHE
The research agent reads CHE's filings, financials, insider trades and 13F holders, then answers with sources.